Eli Lilly (LLY)
(Delayed Data from NYSE)
$862.86 USD
+18.36 (2.17%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $864.09 +1.23 (0.14%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Eli Lilly and Company has a PEG ratio of 1.30 compared to the Large Cap Pharmaceuticals industry's PEG ratio of 1.68.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LLY 862.86 +18.36(2.17%)
Will LLY be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for LLY
Company News for Oct 31, 2025
Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Data Deluge
Pre-markets Down on Questions: Fed, Jobs & Q3 Earnings
Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics
Other News for LLY
Top 15 High-Growth Dividend Stocks For November 2025
MACD Bullish Signal Line Cross appears for LLY after 2.17% move
Eli Lilly Reports Strong Q3 2025 Growth
Eli Lilly price target raised to $950 from $900 at BofA
Eli Lilly price target raised by $50 at BofA, here's why